Customers wanting Botox and dermal fillers at Superdrug face mental health check
The NHS has demanded that Superdrug, which triggered a storm of criticism when it started offering Botox, check for conditions such as body dysmorphic disorder before giving procedures. (Source: the Mail online | Health)
Source: the Mail online | Health - January 19, 2019 Category: Consumer Health News Source Type: news
Botox May Help Prevent Migraines
In comparison to placebos, Botox injections resulted in an average 1.6 fewer attacks per month for those with more than 15 headaches a month. (Source: NYT Health)
Source: NYT Health - January 8, 2019 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Migraine Headaches Botox (Drug) Placebos Source Type: news
Allergan joins biotech swarm in Kendall Square with R & D hub
Yet another of biotech's biggest names is moving to Cambridge.
Irish pharmaceutical giant Allergan plc announced plans Monday to open a research facility in Kendall Square during the first quarter of 2019. Former AstraZeneca and Pfizer executive and current Allergan Senior Vice President of Research and External Scientific Innovation Don Frail will oversee th e site, according to a news release.
The Botox manufacturer did not disclose where the office would be located or how many employees would… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 8, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
People With Movement Disorders May Become Immune to Botox Therapy
FRIDAY, Dec. 28, 2018 -- Some people who receive botulinum toxin injections for disorders that cause muscle tightness and contractions develop resistance to the treatment, researchers say.
The new study included nearly 600 patients with dystonia or... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 28, 2018 Category: General Medicine Source Type: news
Patients May Become Immune to Botulinum Toxin Treatments
TUESDAY, Dec. 11, 2018 -- About 15 percent of patients treated with botulinum toxin type A (BoNT/A) for dystonia or spasticity can develop an immune response to the treatment itself, according to a study published online Nov. 21 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2018 Category: Pharmaceuticals Source Type: news
